Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 Business Wire - Thu Apr 30, 7:25AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS),...

DMAC : 5.91 (-2.31%)
RedChip's Biotech Virtual Investor Conference Replays Now Available ACCESS Newswire - Tue Apr 21, 10:00AM CDT

ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CLDI : 0.2256 (-4.81%)
INAB : 1.4900 (+1.36%)
DMAC : 5.91 (-2.31%)
NSRX : 2.94 (+8.89%)
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms ACCESS Newswire - Tue Apr 7, 6:00AM CDT

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

CLDI : 0.2256 (-4.81%)
INAB : 1.4900 (+1.36%)
CNTB : 2.42 (-2.23%)
DMAC : 5.91 (-2.31%)
NSRX : 2.94 (+8.89%)
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights Business Wire - Mon Mar 30, 3:45PM CDT

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199...

DMAC : 5.91 (-2.31%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.91 (-2.31%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.91 (-2.31%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Fri Mar 27, 4:02PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.91 (-2.31%)
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 Business Wire - Mon Mar 23, 7:25AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS),...

DMAC : 5.91 (-2.31%)
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia Business Wire - Thu Mar 5, 6:35AM CST

“No Objection Letter” from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia...

DMAC : 5.91 (-2.31%)
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences Business Wire - Tue Feb 24, 8:23AM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 5.91 (-2.31%)

Barchart Exclusives

A Short Squeeze Could Trigger in EZCORP Stock as It Trades at New 10-Year Highs Barchart - 5 minutes ago
EZCORP (EZPW) has surged nearly 110% over the past year and is trading at new 10-year highs. The stock maintains a 100% “Buy” technical opinion from Barchart. A high short interest of 16.93% could fuel a potential short squeeze. Despite some views of overvaluation, expansion in target markets and persistent... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.